Background: Potentially inappropriate medications (PIMs) and omissions of medicines among older adults are increasingly popular with the aging population in China.
Objective: PIMs and omissions of medicines among older adults in the community were assessed via three distinct evaluation criteria, thus providing a basis for standardizing medication management in the elderly.
Methods: From April 2021 to June 2021, older adults in the 12 communities were selected from streets or villages in Wuhan, Yichang, Qianjiang and Zhijiang City of Hubei Province (3 streets/villages from each city by cluster sampling). PIMs and omissions of medicines among older adults were evaluated by the 2023 American Geriatrics Society (AGS) Beers Criteria, the 2014 STOPP (Screening Tool of Older Persons' Prescriptions)/START (Screening Tool to Alert to Right Treatment) Criteria, and the 2017 Chinese PIM Criteria for Older Adults.
Results: A total of 1011 eligible older adults in the community were enrolled, including 420 (43.08 %) male and 591 (57.92 %) female patients. Significant differences were detected in the number of medications across subgroups based on the sex, age, and chronic diseases (P < 0.05). Evaluated by the 2023 AGS Beers Criteria, there were 294 (29.08 %) cases of PIMs. A total of 189 (18.69 %) cases of PIMs and 229 omissions of medicines were identified by the 2014 STOPP/START Criteria. Using the 2017 Chinese PIM Criteria for Older Adults, 296 (29.28 %) cases of PIMs were screened out. Nifedipine immediate release (IR), and nifedipine were the most frequently detected drugs of PIMs by the 2023 AGS Beers Criteria, and the 2017 Chinese PIM Criteria for Older Adults, respectively. Evaluated by the 2014 STOPP/START Criteria, non-steroidal anti-inflammatory drugs (NSAIDs) were the leading type of PIMs, and type 2 diabetes mellitus (T2DM) patients without metformin treatment was the top one item of omitted medicine.
Conclusion: PIMs and omissions of medicines among older adults in the community in Hubei Province should be highly concerned, which can be effectively identified via a combination of three evaluation criteria.
Declarations
Not applicable.
Authors' contributions
W. Li, H. Ge, Z. Jin: Data curation, methodology, formal analysis, and visualization. R. Tursun, J. Li, A. Wei: Article review and editing. D. Feng: Conceptualization, supervision, project administration, and overall project responsibility.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Tongji Medical College of HUST (No. 2020S223).
Consent for publication
Not applicable.
Availability of data and materials
Not applicable.
Funding
This research was supported by the National Natural Science Foundation of China (No. 72274071) and the National Natural Science Foundation in Hubei Province (No. 2023AFB1067).
Declaration of Competing Interest
The authors declare that they have no competing interests.
Acknowledgements
Not applicable.
Authors' other information
Not applicable.
| [1] |
Liu YX, Wang J, Yan ZQ, et al. Characteristics and influencing factors of perceived risk of polypharmacy in patients with chronic diseases. Drug Eval. 2021; 40(7):959-963. https://doi.org/10.3870/j.issn.1004-0781.2021.07.024
|
| [2] |
Li YH, Ding L, Li CY, et al. Evaluation of potentially inappropriate medications in 364 elderly inpatients based on beers criteria and STOPP/START criteria. Chin J Prescr Drugs. 2021; 19(2):3-6.
|
| [3] |
Li YY, Yan M, Wang Y. Introduction to the STOPP and START medication review prompts for elderly patients. Chin Pharm. 2015; 18(1):145-148. https://doi.org/10.3969/j.issn.1008-049X.2015.01.051
|
| [4] |
Zhang Q, Li S, Li PM. Interpretation of the 2023 beers criteria for potentially inappropriate medications in the elderly by the American geriatrics society. Chin Gen Pract Med. 2023; 26(35):4372-4381.
|
| [5] |
Elderly Rational Drug Use Branch of the Chinese Society of Geriatric Medicine E, Geriatric Medicine Branch of the Chinese Medical Association, and Geriatric Pharmacy Professional Committee. Guidelines for determining potentially inappropriate medications for the elderly in China (2017 edition). J Advers Drug React. 2018(1):2.
|
| [6] |
Chi JT, Niu XD, Ruan HH, et al. Assessment tools and application progress for potentially inappropriate medications in elderly patients. J Nurs Sci. 2019; 26(23):36-40. https://doi.org/10.16460/j.issn1008-9969.2019.23.036
|
| [7] |
Xu YY, Xu ZJ, Ni YT, et al. Research progress and implications of prescription simplification for elderly individuals in the community. Chin Gen Pract Med. 2022; 25(13):1557-1563.
|
| [8] |
Lu J, Hu QZ, Yang M, et al. Research progress on evaluation standards for potentially inappropriate medications in elderly patients. Drug Eval. 2016; 35(10):1096-1100.
|
| [9] |
Wu HL, Ma XW, Wang N, et al. Research progress on evaluation tools for potentially inappropriate medications in the elderly. China Public Health. 2017; 33(2):324-327. https://doi.org/10.11847/zgggws2017-33-02-41
|
| [10] |
Bing Shu. Study on the evaluation of potentially inappropriate medications in elderly inpatients at a tertiary hospital. Hefei: Anhui Medical University; 2018.
|
| [11] |
Yang XO, Zhuang N, Zhang L, et al. Assessment of beers criteria and STOPP criteria in potentially inappropriate medications for elderly patients in the community. J Clin Ration Drug Use. 2017; 10(21):95-97. https://doi.org/10.15887/j.cnki.13-1389/r.2017.21.047
|
| [12] |
Chen ZY, Li F, Zhao ZG, et al. Research progress on the involvement of pharmacists in managing polypharmacy in elderly patients. Chin Hosp Pharm J. 2018; 38(4):450-453. https://doi.org/10.13286/j.cnki.chinhosppharmacyj.2018.04.22
|
| [13] |
Chen ZY, Liu LG, Tuhadong, et al. Assessment of potentially inappropriate medications in community-dwelling elderly patients based on three criteria. Chin J N Drugs Clin Remedial. 2018; 37(12):700-706. https://doi.org/10.14109/j.cnki.xyylc.2018.12.009
|
| [14] |
Ryan C, O'Mahony D, Kennedy J, et al. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharm. 2009; 68(6):936-947. https://doi.org/10.1111/j.1365-2125.2009.03531.x
|
| [15] |
Jhaveri BN, Patel TK, Barvaliya MJ, et al. Utilization of potentially inappropriate medications in elderly patients in a tertiary care teaching hospital in India. Perspect Clin Res. 2014; 5(4):184-189. https://doi.org/10.4103/2229-3485.140562
|
| [16] |
Kara Ö, Arık G, Kızılarslanoglu MC, et al. Potentially inappropriate prescribing according to the STOPP/START criteria for older adults. Aging Clin Exp Res. 2016; 28(4):761-768. https://doi.org/10.1007/s40520-015-0475-4
|
| [17] |
Rahman MM, Keeton AN, Conner AC, et al. Comparisons of potentially inappropriate medications and outcomes in older adults admitted to the intensive care unit: a retrospective cohort study. J Am Pharm Assoc (2003). 2019; 59(5):678-685. https://doi.org/10.1016/j.japh.2019.05.024
|
| [18] |
Li H, Pu SY, Liu QH, et al. Potentially inappropriate medications in Chinese older adults: the beers criteria compared with the screening tool of older persons' prescriptions criteria. Geriatr Gerontol Int. 2017; 17(11):1951-1958. https://doi.org/10.1111/ggi.12999
|
| [19] |
Wang Y, Liu X, Lin Y, et al. Evaluation of potentially inappropriate medications in elderly inpatients based on beers criteria and STOPP/START criteria. Chin J Clin Pharm. 2023; 32(6):412-417. https://doi.org/10.19577/j.1007-4406.2023.06.003
|
| [20] |
Han J, Liang Y, Shao HX, et al. Analysis of the results of inappropriate medication in elderly inpatients based on beers criteria and STOPP/START criteria. Chin Pharm. 2019; 22(1):116-119.
|
| [21] |
Cheng SD, Zhu JF, Wang CD. Evaluation of potentially inappropriate medications and their influencing factors in hospitalized elderly patients based on beers criteria and STOPP/START criteria. Chin Mod Dr. 2022; 60(34):78-82.
|
| [22] |
Guo HJ, Zhu YL, Hu XX, et al. Evaluation of potentially inappropriate medications in discharge prescriptions of elderly patients in neurology based on beers criteria and STOPP/START criteria. J Clin Drug Ther. 2022; 20(11):65-71.
|
| [23] |
Theken KN, Lee CR, Gong L, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharm Ther. 2020; 108(2):191-200. https://doi.org/10.1002/cpt.1830
|
| [24] |
Sun CH. Analysis of potentially inappropriate medication in elderly inpatients. Changchun: Jilin University; 2023 https://doi.org/10.27162/d.cnki.gjlin.2023.005988
|
| [25] |
Liu JN, Li YB, Wang YL, et al. Research progress and regulatory considerations on reasonable use of traditional Chinese Medicine based on compatibility interactions. Chin Herb Med. 2023; 54(2):375-385.
|
| [26] |
Xu J, Tang ZH. Analysis of adverse reactions to traditional Chinese Medicine injections in 104 children. J Pediatr Pharm. 2024; 30(1):21-23. https://doi.org/10.13407/j.cnki.jpp.1672-108X.2024.01.006
|
| [27] |
Yan ZQ, Feng ZC, Jiao ZM, et al. Safety of using traditional Chinese Medicine injections in primary medical institutions: based on the spontaneous reporting system 2016-2020 in henan province, China. Front Pharm. 2022; 13:761097. https://doi.org/10.3389/fphar.2022.761097
|
PDF
(530KB)
